Skip to main
ETON

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals is positioned for growth, with a successful launch of a new product and a potential licensing deal for a new treatment. However, limited resources and the need for continuous fundraising could impact the company's valuation. Management's conservative approach to guidance is viewed positively, with a Buy rating and a 12-month price target of $65.00 per share, indicating potential for future growth and success.

Bears say

Eton Pharmaceuticals is experiencing a surge in growth, as evidenced by its largest beat and raise in company history due to the rapid ramp-up of its flagship product HEMANGEOL and successful conversion to a single-specialty pharmacy model. However, with the shift to converting off-label adult propranolol use and the development of ASN-001, a potential top product, there are concerns about cannibalization of HEMANGEOL and the need for further commercial build. Additionally, with licensing revenue fluctuating and potential approval for a new pediatric formulation in the pipeline, there may be some instability in the short term, leading to a negative outlook for the stock.

ETON has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 4 analysts, ETON has a Strong Buy consensus rating as of Aug 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.